Ultragenyx EVP Pinion sells $228k in shares

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry South Korean stock trading temporarily halted as KOSPI slides over 11% Asia stocks slide amid Iran tensions, mixed China PMIs; S.Korea slumps 11% Stocks close in the red as widening Middle East conflict sparks inflation fears Gold slips on stronger dollar; safe haven demand remains high amid Iran conflict (South Africa Philippines Nigeria) Ultragenyx EVP Pinion sells $228k in shares By Insider Trading Published 03/04/2026, 12:43 AM Ultragenyx EVP Pinion sells $228k in shares 0 RARE -4.13% Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Executive Vice President, Chief Quality Operations Officer, John Richard Pinion, sold 10,029 shares of common stock on March 2, 2026, for approximately $228,661. The shares were sold at prices ranging from $22.54 to $23.11. The stock currently trades at $22.07, down 48% from its 52-week high of $42.37, though InvestingPro analysis suggests the company remains undervalued at current levels. The transaction follows the conversion of 11,137 performance stock units into common stock on March 1, 2026, with a value of $0. Following the sale, Pinion directly owns 110,026 shares, which includes 490 shares acquired under the Company’s Amended and Restated Employee Stock Purchase Plan on April 30, 2025, and previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. The biotech company faces profitability headwinds, with analysts not anticipating profits this year, according to InvestingPro Tips. In other recent news, Ultragenyx Pharmaceutical Inc. reported its fourth-quarter earnings for 2025, highlighting a mixed financial performance. The company saw a significant revenue increase, reporting $207 million compared to the forecasted $192.15 million, a 7.73% positive surprise. However, the earnings per share fell short of expectations, coming in at -$1.29 against the anticipated -$1.15. In another development, ...